Shanghai Junshi Biosciences Co., Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Cong Li
- Full Time Employees
- 2,578
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 7 Shanghai People's Republic of China 200126
- IPO Date
- Feb 2, 2021
- Website
- junshipharma.com
- Similar Companies
- Business
- Shanghai Junshi Biosciences Co., Ltd. (HKEX: 1877; SSE: 688180; OTC: SHJBF) develops, manufactures and commercializes innovative biopharmaceuticals focused on oncology, autoimmune diseases, metabolic disorders, neurological conditions and infectious diseases; its core products include toripalimab (TUOYI, PD-1 inhibitor; LOQTORZI internationally) approved for multiple indications such as nasopharyngeal carcinoma, esophageal squamous cell carcinoma, melanoma, non-small cell lung cancer, small cell lung cancer and urothelial carcinoma; adalimumab biosimilar (JUNMAIKANG, UBP1211, TNF-α inhibitor) for autoimmune conditions including Crohn's disease; ongericimab (JUNSHIDA, JS002, PCSK9 inhibitor) for hypercholesterolemia and mixed dyslipidemia including statin-intolerant patients; deuremidevir hydrobromide (MINDEWEI, VV116, RdRp inhibitor) for COVID-19; etesevimab for SARS-CoV-2; along with pipeline candidates such as tifcemalimab (BTLA), JS005 (IL-17A) for plaque psoriasis, JS212 (EGFR/HER3 bispecific ADC), JS207 (PD-1 x VEGF bispecific), UBP1213 (BLyS), JS103 (uricase), JS401 (ANGPTL3 siRNA) and JS010 (CGRP). Founded in 2012 and headquartered in Shanghai, China, the company operates innovation centers in Shanghai, Suzhou and Maryland, US, with production bases in Suzhou Wujiang and Shanghai Lingang, targeting patients globally through partnerships and serving primarily oncologists, rheumatologists, cardiologists and infectious disease specialists in China and expanding internationally. Recent developments encompass strategic commercialization alliances including a January 2025 distribution and marketing partnership with LEO Pharma for toripalimab (LOQTORZI) in Europe, prior collaborations with Coherus BioSciences for the US and Canada, Dr. Reddy's Laboratories for 21 countries, Rxilient Biotech for Southeast Asia and Hikma for the Middle East and North Africa; regulatory milestones feature NMPA approvals for ongericimab's supplemental NDAs in 2025 for statin-intolerant patients, toripalimab's 12th indication for first-line melanoma, sNDA acceptance for HER2-expressing urothelial carcinoma and Phase 3 success for JS005 in plaque psoriasis; international approvals include toripalimab in Singapore, UAE, Kuwait, Pakistan, Canada, UK, Australia and European Commission for NPC and ESCC; pipeline advances such as IND approval for JS212 in March 2025 and robust H1 2025 revenue growth of 49% driven by toripalimab expansions and NRDL inclusion.
Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026
Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
TREOS Bio Partners with Charité Berlin and Junshi Biosciences to Launch Pivotal Phase II Clinical Trial in Refractory MSS Colorectal Cancer
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates